Small-molecule pan-IAP antagonists: a patent review

Bibliography

• Ashkenazi A, Dixit VM. Apoptosis control by death and decoy receptors. Curr Opin Cell Biol 1999;11:255-60
   PubMed Web of Science ®Google Scholar
• Crook NE, Clem RJ, Miller LK. An apoptosis-inhibiting baculovirus gene with a zinc finger-like motif. J Virol 1993;67:2168-74
   PubMed Web of Science ®Google Scholar
• Birnbaum MJ, Clem RJ, Miller LK. An apoptosis-inhibiting gene from a nuclear polyhedrosis virus encoding a polypeptide with Cys/His sequence motifs. J Virol 1994;68:2521-8
   PubMed Web of Science ®Google Scholar
• Clem RJ, Miller LK. Control of programmed cell death by the baculovirus genes p35 and iap. Mol Cell Biol 1994;14:5212-22
   PubMed Web of Science ®Google Scholar
• Vucic D, Stennicke HR, Pisabarro MT, ML-IAP, a novel inhibitor of apoptosis that is preferentially expressed in human melanomas. Curr Biol 2000;10:1359-66
   PubMed Web of Science ®Google Scholar
• Imoto I, Yang ZQ, Pimkhaokham A, Identification of cIAP1 As a candidate target gene within an amplicon at 11q22 in esophageal squamous cell carcinomas. Cancer Res 2001;61:6629-34
   PubMed Web of Science ®Google Scholar
• Imoto I, Tsuda H, Hirasawa A, Expression of cIAP1, a target for 11q22 amplification, correlates with resistance of cervical cancers to radiotherapy. Cancer Res 2002;62:4860-6
   PubMed Web of Science ®Google Scholar
• Yang L, Cao Z, Yan H, Wood WC. Coexistence of high levels of apoptotic signaling and inhibitor of apoptosis proteins in human tumor cells: implication for cancer specific therapy. Cancer Res 2003;63:6815-24
   PubMed Web of Science ®Google Scholar
• Hunter AM, LaCasse EC, Korneluk RG. The inhibitors of apoptosis (IAPs) as cancer targets. Apoptosis 2007;12:1543-68
   PubMed Web of Science ®Google Scholar
• Salvesen GS, Duckett CS. IAP proteins: blocking the road to death's door. Nat Rev Mol Cell Biol 2002;3:401-10
   PubMed Web of Science ®Google Scholar
• Liston P, Fong WG, Korneluk RG. The inhibitors of apoptosis: there is more to life than Bcl2. Oncogene 2003;22:8568-80
   PubMed Web of Science ®Google Scholar
• Nachmias B, Ashhab Y, Ben-Yehuda D. The inhibitor of apoptosis protein family (IAPs): an emerging therapeutic target in cancer. Semin Cancer Biol 2004;14:231-43
   PubMed Web of Science ®Google Scholar
• Schimmer AD. Inhibitor of apoptosis proteins: translating basic knowledge into clinical practice. Cancer Res 2004;64:7183-90
   PubMed Web of Science ®Google Scholar
• Wright CW, Duckett CS. Reawakening the cellular death program in neoplasia through the therapeutic blockade of IAP function. J Clin Invest 2005;115:2673-8
   PubMedGoogle Scholar
• Vucic D, Fairbrother WJ. The inhibitor of apoptosis proteins as therapeutic targets in cancer. Clin Cancer Res 2007;13:5995-6000
   PubMed Web of Science ®Google Scholar
• Sasaki H, Sheng Y, Kotsuji F, Tsang BK. Down-regulation of X-linked inhibitor of apoptosis protein induces apoptosis in chemoresistant human ovarian cancer cells. Cancer Res 2000;60:5659-66
   PubMed Web of Science ®Google Scholar
• Kasof GM, Gomes BC. Livin, a novel inhibitor of apoptosis protein family member. J Biol Chem 2001;276:3238-46
   PubMed Web of Science ®Google Scholar
• Li J, Feng Q, Kim JM, Human ovarian cancer and cisplatin resistance: possible role of inhibitor of apoptosis proteins. Endocrinology 2001;142:370-80
   PubMed Web of Science ®Google Scholar
• Lin H, Chen C, Chen BD. Resistance of bone marrow-derived macrophages to apoptosis is associated with the expression of X-linked inhibitor of apoptosis protein in primary cultures of bone marrow cells. Biochem J 2001;353:299-306
   PubMed Web of Science ®Google Scholar
• Gordon GJ, Appasani K, Parcells JP, Inhibitor of apoptosis protein-1 promotes tumor cell survival in mesothelioma. Carcinogenesis 2002;23:1017-24
   PubMed Web of Science ®Google Scholar
• Bilim V, Kasahara T, Hara N, Role of XIAP in the malignant phenotype of transitional cell cancer (TCC) and therapeutic activity of XIAP antisense oligonucleotides against multidrug-resistant TCC in vitro. Int J Cancer 2003;103:29-37
   PubMed Web of Science ®Google Scholar
• Crnkovic-Mertens I, Hoppe-Seyler F, Butz K. Induction of apoptosis in tumor cells by siRNA-mediated silencing of the livin/ML-IAP/KIAP gene. Oncogene 2003;22:8330-6
   Google Scholar
• Hu Y, Cherton-Horvat G, Dragowska V, Antisense oligonucleotides targeting XIAP induce apoptosis and enhance chemotherapeutic activity against human lung cancer cells in vitro and in vivo. Clin Cancer Res 2003;9:2826-36
   PubMed Web of Science ®Google Scholar
• Cummins JM, Kohli M, Rago C, X-linked inhibitor of apoptosis protein (XIAP) is a nonredundant modulator of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis in human cancer cells. Cancer Res 2004;64:3006-8
   PubMed Web of Science ®Google Scholar
• McEleny K, Coffey R, Morrissey C, An antisense oligonucleotide to cIAP-1 sensitizes prostate cancer cells to fas and TNFalpha mediated apoptosis. Prostate 2004;59:419-25
   PubMed Web of Science ®Google Scholar
• McManus DC, Lefebvre CA, Cherton-Horvat G, Loss of XIAP protein expression by RNAi and antisense approaches sensitizes cancer cells to functionally diverse chemotherapeutics. Oncogene 2004;23:8105-17
   PubMed Web of Science ®Google Scholar
• Crnkovic-Mertens I, Semzow J, Hoppe-Seyler F, Butz K. Isoform-specific silencing of the Livin gene by RNA interference defines Livin beta as key mediator of apoptosis inhibition in HeLa cells. J Mol Med 2006;84:232-40
   Google Scholar
• Crnkovic-Mertens I, Wagener N, Semzow J, Targeted inhibition of Livin resensitizes renal cancer cells towards apoptosis. Cell Mol Life Sci 2007;64:1137-44
   Google Scholar
• Chu ZL, McKinsey TA, Liu L, Suppression of tumor necrosis factor-induced cell death by inhibitor of apoptosis c-IAP2 is under NF-κB control. Proc Natl Acad Sci USA 1997;94:10057-62
   PubMed Web of Science ®Google Scholar
• Hofer-Warbinek R, Schmid JA, Stehlik C, Activation of NF-κB by XIAP, the X chromosome-linked inhibitor of apoptosis, in endothelial cells involves TAK1. J Biol Chem 2000;275:22064-8
   Google Scholar
• Asselin E, Mills GB, Tsang BK. XIAP regulates Akt activity and caspase-3-dependent cleavage during cisplatin-induced apoptosis in human ovarian epithelial cancer cells. Cancer Res 2001;61:1862-8
   PubMed Web of Science ®Google Scholar
• Birkey Reffey S, Wurthner JU, Parks WT, X-linked inhibitor of apoptosis protein functions as a cofactor in transforming growth factor-beta signaling. J Biol Chem 2001;276:26542-9
   PubMed Web of Science ®Google Scholar
• Sanna MG, da Silva Correia J, Ducrey O, IAP suppression of apoptosis involves distinct mechanisms: the TAK1/JNK1 signaling cascade and caspase inhibition. Mol Cell Biol 2002;22:1754-66
   PubMed Web of Science ®Google Scholar
• Zhao Y, Conze DB, Hanover JA, Ashwell JD. Tumor necrosis factor receptor 2 signaling induces selective c-IAP1-dependent ASK1 ubiquitination and terminates mitogen-activated protein kinase signaling. J Biol Chem 2007;282:7777-82
   Google Scholar
• Xu L, Zhu J, Hu X, c-IAP1 cooperates with Myc by acting as a ubiquitin ligase for Mad1. Mol Cell 2007;28:914-22
   PubMed Web of Science ®Google Scholar
• Varfolomeev E, Blankenship JW, Wayson SM, IAP antagonists induce autoubiquitination of c-IAPs, NF-κB activation, and TNFalpha-dependent apoptosis. Cell 2007;131:669-81
   PubMed Web of Science ®Google Scholar
• Dogan T, Harms GS, Hekman M, X-linked and cellular IAPs modulate the stability of C-RAF kinase and cell motility. Nat Cell Biol 2008;10:1447-55
   PubMed Web of Science ®Google Scholar
• Bertrand MJ, Milutinovic S, Dickson KM, cIAP1 and cIAP2 facilitate cancer cell survival by functioning as E3 ligases that promote RIP1 ubiquitination. Mol Cell 2008;30:689-700
   PubMed Web of Science ®Google Scholar
• Mahoney DJ, Cheung HH, Mrad RL, Both cIAP1 and cIAP2 regulate TNFalpha-mediated NF-κB activation. Proc Natl Acad Sci USA 2008;105:11778-83
   PubMed Web of Science ®Google Scholar
• Varfolomeev E, Goncharov T, Fedorova AV, c-IAP1 and c-IAP2 are critical mediators of tumor necrosis factor alpha (TNFalpha)-induced NF-κB activation. J Biol Chem 2008;283:24295-9
   PubMed Web of Science ®Google Scholar
• Varfolomeev E, Vucic D. (Un)expected roles of c-IAPs in apoptotic and NFκB signaling pathways. Cell Cycle 2008;7:1511-21
   PubMed Web of Science ®Google Scholar
• Vaux DL, Silke J. IAPs, RINGs and ubiquitylation. Nat Rev Mol Cell Biol 2005;6:287-97
   PubMed Web of Science ®Google Scholar
• Gyrd-Hansen M, Darding M, Miasari M, IAPs contain an evolutionarily conserved ubiquitin-binding domain that regulates NF-κB as well as cell survival and oncogenesis. Nat Cell Biol 2008;10:1309-17
   PubMed Web of Science ®Google Scholar
• Blankenship JW, Varfolomeev E, Goncharov T, Ubiquitin binding modulates IAP antagonist-stimulated proteasomal degradation of c-IAP1 and c-IAP2. Biochem J 2009;417:149-60
   PubMed Web of Science ®Google Scholar
• Takahashi R, Deveraux Q, Tamm I, A single BIR domain of XIAP sufficient for inhibiting caspases. J Biol Chem 1998;273:7787-90
   PubMed Web of Science ®Google Scholar
• Sun C, Cai M, Gunasekera AH, NMR structure and mutagenesis of the inhibitor-of-apoptosis protein XIAP. Nature 1999;401:818-22
   PubMed Web of Science ®Google Scholar
• Chai J, Shiozaki E, Srinivasula SM, Structural basis of caspase-7 inhibition by XIAP. Cell 2001;104:769-80
   PubMed Web of Science ®Google Scholar
• Huang Y, Park YC, Rich RL, Structural basis of caspase inhibition by XIAP: differential roles of the linker versus the BIR domain. Cell 2001;104:781-90
   PubMed Web of Science ®Google Scholar
• Riedl SJ, Renatus M, Schwarzenbacher R, Structural basis for the inhibition of caspase-3 by XIAP. Cell 2001;104:791-800
   PubMed Web of Science ®Google Scholar
• Deveraux QL, Leo E, Stennicke HR, Cleavage of human inhibitor of apoptosis protein XIAP results in fragments with distinct specificities for caspases. EMBO J 1999;18:5242-51
   PubMed Web of Science ®Google Scholar
• Sun C, Cai M, Meadows RP, NMR structure and mutagenesis of the third BIR domain of the inhibitor of apoptosis protein XIAP. J Biol Chem 2000;275:33777-81
   PubMedGoogle Scholar
• Srinivasula SM, Hegde R, Saleh A, A conserved XIAP-interaction motif in caspase-9 and Smac/DIABLO regulates caspase activity and apoptosis. Nature 2001;410:112-16
   PubMed Web of Science ®Google Scholar
• Shiozaki EN, Chai J, Rigotti DJ, Mechanism of XIAP-mediated inhibition of caspase-9. Mol Cell 2003;11:519-27
   PubMed Web of Science ®Google Scholar
• Silke J, Hawkins CJ, Ekert PG, The anti-apoptotic activity of XIAP is retained upon mutation of both the caspase 3- and caspase 9-interacting sites. J Cell Biol 2002;157:115-24
   PubMed Web of Science ®Google Scholar
• Du C, Fang M, Li Y, Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell 2000;102:33-42
   PubMed Web of Science ®Google Scholar
• Verhagen AM, Ekert PG, Pakusch M, Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins. Cell 2000;102:43-53
   PubMed Web of Science ®Google Scholar
• Chai J, Du C, Wu JW, Structural and biochemical basis of apoptotic activation by Smac/DIABLO. Nature 2000;406:855-62
   PubMed Web of Science ®Google Scholar
• Liu Z, Sun C, Olejniczak ET, Structural basis for binding of Smac/DIABLO to the XIAP BIR3 domain. Nature 2000;408:1004-8
   PubMed Web of Science ®Google Scholar
• Wu G, Chai J, Suber TL, Structural basis of IAP recognition by Smac/DIABLO. Nature 2000;408:1008-12
   PubMed Web of Science ®Google Scholar
• Srinivasula SM, Datta P, Kobayashi M, Sickle, a novel drosophila death gene in the reaper/hid/grim region, encodes an iap-inhibitory protein. Curr Biol 2002;12:125-30
   PubMedGoogle Scholar
• Franklin MC, Kadkhodayan S, Ackerly H, Structure and function analysis of peptide antagonists of melanoma inhibitor of apoptosis (ML-IAP). Biochemistry 2003;42:8223-31
   PubMed Web of Science ®Google Scholar
• Wu JW, Cocina AE, Chai J, Structural analysis of a functional DIAP1 fragment bound to grim and hid peptides. Mol Cell 2001;8:95-104
   PubMedGoogle Scholar
• Scott FL, Denault JB, Riedl SJ, XIAP inhibits caspase-3 and -7 using two binding sites: evolutionarily conserved mechanism of IAPs. EMBO J 2005;24:645-55
   PubMed Web of Science ®Google Scholar
• Vucic D, Franklin MC, Wallweber HJ, Engineering ML-IAP to produce an extraordinarily potent caspase 9 inhibitor: implications for Smac-dependent anti-apoptotic activity of ML-IAP. Biochem J 2005;385:11-20
   PubMedGoogle Scholar
• Eckelman BP, Salvesen GS. The human anti-apoptotic proteins cIAP1 and cIAP2 bind but do not inhibit caspases. J Biol Chem 2006;281:3254-60
   PubMed Web of Science ®Google Scholar
• Eckelman BP, Salvesen GS, Scott FL. Human inhibitor of apoptosis proteins: why XIAP is the black sheep of the family. EMBO Rep 2006;7:988-94
   PubMed Web of Science ®Google Scholar
• Shin H, Renatus M, Eckelman BP, The BIR domain of IAP-like protein 2 is conformationally unstable: implications for caspase inhibition. Biochem J 2005;385:1-10
   Google Scholar
• Duckett CS. IAP proteins: sticking it to Smac. Biochem J 2005;385:e1-2
   PubMedGoogle Scholar
• Vucic D, Deshayes K, Ackerly H, SMAC negatively regulates the anti-apoptotic activity of melanoma inhibitor of apoptosis (ML-IAP). J Biol Chem 2002;277:12275-9
   PubMed Web of Science ®Google Scholar
• Guo F, Nimmanapalli R, Paranawithana S, Ectopic overexpression of second mitochondria-derived activator of caspases (Smac/DIABLO) or cotreatment with N-terminus of Smac/DIABLO peptide potentiates epothilone B derivative-(BMS 247550) and Apo-2L/TRAIL-induced apoptosis. Blood 2002;99:3419-26
   PubMed Web of Science ®Google Scholar
• Arnt CR, Chiorean MV, Heldebrant MP, Synthetic Smac/DIABLO peptides enhance the effects of chemotherapeutic agents by binding XIAP and cIAP1 in situ. J Biol Chem 2002;277:44236-43
   PubMed Web of Science ®Google Scholar
• Fulda S, Wick W, Weller M, Debatin KM. Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo. Nat Med 2002;8:808-15
   PubMed Web of Science ®Google Scholar
• Board of Regents. The University of Texas System. Activators of caspases. US6110691A; 2000
   Google Scholar
• Vince JE, Wong WW, Khan N, IAP antagonists target cIAP1 to induce TNFalpha-dependent apoptosis. Cell 2007;131:682-93
   PubMed Web of Science ®Google Scholar
• Petersen SL, Wang L, Yalcin-Chin A, Autocrine TNFalpha signaling renders human cancer cells susceptible to Smac-mimetic-induced apoptosis. Cancer Cell 2007;12:445-56
   PubMed Web of Science ®Google Scholar
• Wang L, Du F, Wang X. TNF-alpha induces two distinct caspase-8 activation pathways. Cell 2008;133:693-703
   PubMed Web of Science ®Google Scholar
• Ndubaku C, Varfolomeev E, Wang L, Antagonism of c-IAP and XIAP proteins is required for efficient induction of cell death by small-molecule IAP antagonists. ACS Chem Biol 2009;4:557-66
   Google Scholar
• Kipp RA, Case MA, Wist AD, Molecular targeting of inhibitor of apoptosis proteins based on small molecule mimics of natural binding partners. Biochemistry 2002;41:7344-9
   PubMed Web of Science ®Google Scholar
• Abbott Laboratories. Peptides derived from Smac (DIABLO) and methods of use therefor. WO2002030959A2; 2001
   Google Scholar
• Genentech, Inc. Compositions and methods for enhancing apoptosis. WO2004072641A1; 2003
   Google Scholar
• Oost TK, Sun C, Armstrong RC, Discovery of potent antagonists of the antiapoptotic protein XIAP for the treatment of cancer. J Med Chem 2004;47:4417-26
   PubMed Web of Science ®Google Scholar
• Deutsches Krebsforschungszentrum. Smac-peptides as therapeutics against cancer and autoimmune diseases. WO2003086470A2; 2003
   Google Scholar
• The Regents of the University of Michigan. Conformationally Constrained Smac Mimetics and the Uses Thereof. US20080269140A1; 2008
   Google Scholar
• Novartis AG. Organic compounds. US7419975B2; 2005
   Google Scholar
• Chauhan D, Neri P, Velankar M, Targeting mitochondrial factor Smac/DIABLO as therapy for multiple myeloma (MM). Blood 2007;109:1220-7
   PubMed Web of Science ®Google Scholar
• Idun Pharmaceuticals, Inc. Tetrapeptide analogs. WO2006017295A2; 2005
   Google Scholar
• The Trustees of Princeton University. IAP binding compounds. WO2004007529A3; 2003
   Google Scholar
• Novartis AG. Organic compounds. WO2006133147A2; 2006
   Google Scholar
• Novartis AG. 6-Oxo.-1, 6-dihydropyrimidin-2-yls in the treatment of proliferative diseases. WO2008073305A1; 2007
   Google Scholar
• Novartis AG. Organic compounds. WO2008073306A1; 2007
   Google Scholar
• Aegera Therapeutics, Inc. BIR domain binding compounds. WO2007101347A1; 2007
   Google Scholar
• Genentech, Inc. Inhibitors of IAP. US7244851B2; 2005
   Google Scholar
• Zobel K, Wang L, Varfolomeev E, Design, synthesis, and biological activity of a potent Smac mimetic that sensitizes cancer cells to apoptosis by antagonizing IAPs. ACS Chem Biol 2006;1:525-33
   PubMed Web of Science ®Google Scholar
• The Regents of the University of Michigan. Diazo bicyclic smac mimetics and the uses thereof. WO2008128171A3; 2008
   Google Scholar
• Genentech, Inc. Azabicyclo-octane inhibitors of IAP. US7345081B2; 2005
   Google Scholar
• Cohen F, Alicke B, Elliott LO, Orally bioavailable antagonists of inhibitor of apoptosis proteins based on an azabicyclooctane scaffold. J Med Chem 2009;52:1723-30
   Google Scholar
• Tetralogic Pharmaceuticals Corporation. IAP binding compounds. US7456209B2; 2005
   Google Scholar
• Genentech, Inc. Pyrrolidine inhibitors of IAP. WO2006069063A1; 2005
   Google Scholar
• Board of Regents. The University of Texas System. Dimeric small molecule potentiators of apoptosis. US7309792B2; 2005
   Google Scholar
• Li L, Thomas RM, Suzuki H, A small molecule Smac mimic potentiates TRAIL- and TNFalpha-mediated cell death. Science 2004;305:1471-4
   PubMed Web of Science ®Google Scholar
• Cossu F, Milani M, Mastrangelo E, Structural basis for bivalent smac-mimetics recognition in the IAP protein family. J Mol Biol 2009;392:630-44
   Google Scholar
• Aegera Therpeutics, Inc. IAP BIR domain binding compounds. US7547724B2; 2006
   Google Scholar
• Aegera Therapeutics, Inc. IAP BIR domain binding compounds. US7589118B2; 2006
   Google Scholar
• Aegera Therapeutics, Inc. IAP BIR domain binding compounds. US7579320B2; 2007
   Google Scholar
• Aegera Therapeutics, Inc. IAP BIR domain binding compounds. WO2007131366A1; 2007
   Google Scholar
• Universita'Degli Studi di Milano Fondazione IRCCS Istituto Nazionale dei Tumori. Smac mimetic compounds as apoptosis inducers. WO2009060292A3; 2008
   Google Scholar
• Genentech, Inc. Inhibitors of IAP. WO2008134679A1; 2008
   Google Scholar
• The Regents of the University of Michigan. Bivalent Smac mimetics and the uses thereof. WO2007130626A2; 2007
   Google Scholar
• Sun H, Nikolovska-Coleska Z, Lu J, Design, synthesis, and characterization of a potent, nonpeptide, cell-permeable, bivalent Smac mimetic that concurrently targets both the BIR2 and BIR3 domains in XIAP. J Am Chem Soc 2007;129:15279-94
   PubMed Web of Science ®Google Scholar
• TetraLogic Pharmaceuticals Corporation. Dimeric IAP inhibitors. US7517906B2; 2006
   Google Scholar
• Joyant Pharmaceuticals, Inc. Small molecule apoptosis promoters. WO2007136921A3; 2007
   Google Scholar
• Joyant Pharmaceuticals, Inc. Smac mimetic dimers and trimers useful as anti-cancer agents. WO2008128121A1; 2008
   Google Scholar